Cargando…
Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599381/ https://www.ncbi.nlm.nih.gov/pubmed/23497102 http://dx.doi.org/10.1186/1743-422X-10-72 |
_version_ | 1782262950533267456 |
---|---|
author | Ross, R Stefan Stambouli, Oumaima Grüner, Nico Marcus, Ulrich Cai, Wei Zhang, Weidong Zimmermann, Ruth Roggendorf, Michael |
author_facet | Ross, R Stefan Stambouli, Oumaima Grüner, Nico Marcus, Ulrich Cai, Wei Zhang, Weidong Zimmermann, Ruth Roggendorf, Michael |
author_sort | Ross, R Stefan |
collection | PubMed |
description | BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the worldwide leading platform in this field of infection diagnostics. METHODS: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests. RESULTS: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2, HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%, respectively. DISCUSSION/CONCLUSIONS: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity. |
format | Online Article Text |
id | pubmed-3599381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35993812013-03-17 Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification Ross, R Stefan Stambouli, Oumaima Grüner, Nico Marcus, Ulrich Cai, Wei Zhang, Weidong Zimmermann, Ruth Roggendorf, Michael Virol J Research BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the worldwide leading platform in this field of infection diagnostics. METHODS: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests. RESULTS: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2, HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%, respectively. DISCUSSION/CONCLUSIONS: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity. BioMed Central 2013-03-05 /pmc/articles/PMC3599381/ /pubmed/23497102 http://dx.doi.org/10.1186/1743-422X-10-72 Text en Copyright ©2013 Ross et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Ross, R Stefan Stambouli, Oumaima Grüner, Nico Marcus, Ulrich Cai, Wei Zhang, Weidong Zimmermann, Ruth Roggendorf, Michael Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title | Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title_full | Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title_fullStr | Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title_full_unstemmed | Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title_short | Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification |
title_sort | detection of infections with hepatitis b virus, hepatitis c virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the architect system and two commercial assays for nucleic acid amplification |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599381/ https://www.ncbi.nlm.nih.gov/pubmed/23497102 http://dx.doi.org/10.1186/1743-422X-10-72 |
work_keys_str_mv | AT rossrstefan detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT stamboulioumaima detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT grunernico detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT marcusulrich detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT caiwei detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT zhangweidong detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT zimmermannruth detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification AT roggendorfmichael detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification |